Igm Biosciences (IGMS) has disclosed a new risk, in the Trade Secrets category.
Igm Biosciences faces a significant business risk should it pursue federal funding for its research, as it would then be subject to the Bayh-Dole Act stipulations. This legislation grants the U.S. government certain rights to inventions developed with public funds, including the possibility of “march-in” rights, which allow the government to authorize third-party use of Igm Biosciences’ inventions without guaranteeing compensation. Additionally, the U.S. government’s preference for domestic manufacturing could constrain Igm Biosciences’ operational flexibility, potentially undermining its competitive edge and impacting its financial stability.
Overall, Wall Street has a Strong Buy consensus rating on IGMS stock based on 3 Buys and 1 Hold.
To learn more about Igm Biosciences’ risk factors, click here.
